As expected, the FDA hit Avanir Pharmaceuticals Inc. late Wednesday with a complete response letter related to the NDA for AVP-825 for the acute treatment of migraine.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
